Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 18
Healthy volunteers: yes

Brief summary:
The purpose of this study is to measure how much of the new LY2409021 tablet formulations get into the blood stream and how long it takes the body to get rid of them, compared to the current LY2409021 capsule formulation. In addition, the safety and tolerability of both the new and current formulations will be evaluated. Information about any side effects that may occur will also be collected. The study has two parts. Each participant may enroll in one part only. The study will last up to 8 weeks for each participant. Screening is required prior to the start of the study.

Detailed description:

Arms:
arm 1: Single oral dose of LY2409021 capsule in one of three study periods. arm 2: Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods. arm 3: Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods. arm 4: Single oral dose of LY2409021 capsule in one of two study periods. arm 5: Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.

Interventions: intervention 1: LY2409021
Intervention descriptions: intervention 1: Administered orally

Protocol document: